Analysis of Survival in Cancer Clinical Trials
Authors: David Shimm, Gerald Logue
Journal: Annals of Internal Medicine (1983)

Editorials1 May 1983Analysis of Survival in Cancer Clinical TrialsDAVID SHIMM, M.D., GERALD LOGUE, M.D.DAVID SHIMM, M.D.Search for more papers by this author, GERALD LOGUE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-5-665 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe value of the randomized trial for the evaluation of new cancer therapies is undisputed. However, because such trials often do not accrue sufficient numbers of patients in a period of time short enough to be practical (especially when the disease under study is not particularly common), investigators often resort to alternatives to the randomized control group.Several recently published clinical studies using chemotherapy for patients with solid tumors have reported survival data by comparing the actuarial survival of patients responding to chemotherapy to the survival of patients not responding to chemotherapy (1-3). Invariably, patients who respond survive longer than...References1. WOODS R, FOX R, TATTERSALL M, LEVI J, and BRODIE G. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination chemotherapy regimens. N Engl J Med. 1980;303:87-9. CrossrefMedlineGoogle Scholar2. MACDONALD J, SCHEIN P, and WOOLLEY P. 5-Fluorouracil, doxorubicin, and mitocycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980;93:533-6. LinkGoogle Scholar3. GRALLA R, CASPER E, and KELSEN D. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized clinical trial investigating two dosage schedules. Ann Intern Med. 1981;95:414-20. LinkGoogle Scholar4. ROSEN G, TAN C, SANMANEECHAI A, BEATTIE E, MARCOVE R, and MURPHY M. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer. 1975;35:936-45. CrossrefMedlineGoogle Scholar5. ROSEN G, NIRENBERG A, and CAPARROS B. Osteogenic sarcoma: eighty percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr. 1981;56:213-20. Google Scholar6. ROSEN G, CAPARROS B, and HUVOS A. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-30. CrossrefMedlineGoogle Scholar7. TAYLOR W, IVINS J, DAHLIN D, EDMONDSON J, and PRITCHARD D. Trends and variability in survival from osteosarcoma. Mayo Clin Proc. 1978;53:695-700. MedlineGoogle Scholar8. IVERSEN T, KJØRSTAD K, and MARTIMBEAU P. Treatment results in carcinoma of the cervix stage IB in a total population. Gynec Oncol. 1982;14:1-5. CrossrefMedlineGoogle Scholar9. ATKINS H, HAYWARD J, KLUGMAN D, and WAYTE A. Treatment of early breast cancer: a report after 10 years of a clinical trial. Br Med J. 1972;2:423-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DAVID SHIMM, M.D.; GERALD LOGUE, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAdjuvant therapy of cutaneous malignant melanoma: A critical reviewChanging metastatic patterns of osteosarcomaPrestigious Journals and Flawed PapersSAUL B. GILSON, M.D. 1 May 1983Volume 98, Issue 5_Part_1Page: 665-666KeywordsChemotherapyClinical trialsRandomized trialsResearch designSurvival analysis ePublished: 1 December 2008 Issue Published: 1 May 1983 PDF downloadLoading ...